AD)		

Award Number: DAMD17-98-1-8216

TITLE: Determination of Catechol Estrogen Adducts by High-Performance Liquid Chromatography: Establishing Biomarkers for the Early Detection of Breast Cancer

PRINCIPAL INVESTIGATOR: Douglas Stack, Ph.D.

CONTRACTING ORGANIZATION: University of Nebraska
Omaha, Nebraska 68182-0109

REPORT DATE: July 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188). Washington, DC 20503

1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED							
	July 2001	Annual (1 Jun 0					
4. TITLE AND SUBTITLE			5. FUNDING N				
Determination of Catec	DAMD17-98	-1-8216					
Performance Liquid Chr	omatography: Establish	ning Biomarkers		•			
for the Early Detection	n of Breast Cancer						
6. AUTHOR(S)							
Douglas Stack, Ph.D.							
7. PERFORMING ORGANIZATION N	AMF(S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION				
University of Nebraska at Omaha			REPORT NUMBER				
Omaha, Nebraska 68182-0109							
Omana, Neoraska 00102 0105							
E-MAIL:							
destack@unomaha.edu							
9. SPONSORING / MONITORING A	GENCY NAME(S) AND ADDRESS(ES	S)	10. SPONSORING / MONITORING AGENCY REPORT NUMBER				
			AGENCY F	REPORT NOMBER			
U.S. Army Medical Research and							
Fort Detrick, Maryland 21702-5	012						
11. SUPPLEMENTARY NOTES							
				•			
12a. DISTRIBUTION / AVAILABILIT	Y STATEMENT			12b. DISTRIBUTION CODE			
Approved for public release; dist							
-							
13. ABSTRACT (Maximum 200 Wo	rds)	wasan matahalian	, ag it ro	lates to breast			
In order to better und	erstand the role of est	hat can measure	CE and CE	-DNA adducts at low			
cancer etiology, a new analytical technique that can measure CE and CE-DNA adducts at low							
endogenous levels is being developed. This new technique is based on HPLC analysis of fluorescent probes specific for CE and CE-DNA adducts. An extraction procedure employing							
a solvent mixture of chloroform, dimethylforamide, and acetic acid was developed to							
extract CE-DNA adducts	. CE. and MPEM from rat	breast tissue.	This ext	raction procedure			
extract CE-DNA adducts, CE, and MPEM from rat breast tissue. This extraction procedure involves homogenization of the tissue in 20 mL of the solvent mixture, removal of the							
solvent, followed by HPLC analysis. Reaction of α, α -dibromomalonates occurs quickly with							
catechols, and this malonate system is being developed to produce fluorescent probes for							
HPLC analysis. Reaction of diethyl α,α -dibromomalonate with catechol results in ketal							
formation. The resulting ethyl ester is tranesterified to incorporate anthracene groups.							
A one-step process using α,α -dibromomalonamides is also under development. The aim of this							
work is to develop new biomarkers for the early detection of breast cancer.							
14. SUBJECT TERMS		15. NUMBER OF PAGES					
Breast Cancer, Biomark	1	10					
		16. PRICE CODE					
		40.0001010101010101010101010101010101010		OO LIMITATION OF ADORDADA			
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFI OF ABSTRACT	ICATION	20. LIMITATION OF ABSTRACT			
Unclassified	Unclassified	Unclassifi	ed	Unlimited			
				JIII I I COQ			

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

TABLE OF CONTENTS

Cover	1
SF-298	2
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	5
Reportable Outcomes	5
Conclusions	
References	6
Appendices	

INTRODUCTION:

The metabolism of estrogen to procarcinogenic catechols has been hypothesized as an initiation step in the development of breast cancer [1-4]. Specifically, the over expression of 4-hydroxylase activity has been observed in organs prone to estrogen-induced tumors [5-8]. The relationship between increased production of 4-hydroxyestradiol (4-OHE₂) and 4-hydroxyestrone (4-OHE₁) metabolites with the increase occurrence of estrogen-induced tumors is still not clear. Hypothesis regarding redox cycling [9-13] and oxidation to electrophilic quinones have been examined [3,4]. Since oxidation of catechol estrogens (CE) to catechol estrogen quinones (CE-Q) has been shown to lead to CE-DNA adducts [4], we seek to develop an analytical technique that can measure these adducts at endogenous levels. The purpose of developing this assay is to examine whether CE-DNA adducts are present in breast cancer tissue. This would be a first step in understanding the etiology of breast cancer as it relates to estrogen metabolism, specifically, the role of 4-hydroxylase activity in the increase occurrence of estrogen-induced cancers. The scope of this method development involves the production of fluorescent probes, specific for the catechol moiety, so that low-level detection of these adducts can be accomplished. With the proper development of fluorescent probes, this assay would be very sensitive and selective towards CE-DNA adducts.

BODY:

Work relating to Task 1, "Develop an extraction procedure for the isolation of CE-adducts, CE and MPEM from rat mammary tissue", has been nearly completed. CE-DNA adducts, CE, and monophenol estrogen metabolites (MPEM) were added to ca. 0.5 g of rat mammary tissue (Sprague Dawley). The compounds were applied to the tissue in dimethylforamide (DMF) solutions and allowed to stay in contact with the tissue for one hour at room temperature. The tissue was then homogenized in a 50 mL centrifuge tube for 2 minutes using 20 mL of an optimized solvent mixture. The solvent mixture consisted of 55:40:5, chloroform, DMF, and acetic acid, respectively, containing 0.5g-per 100mL ascorbic acid. This solvent mixture has several advantages: 1) by employing greater than 50% chloroform, the mixture is non-flammable and can be used by conventional, metal-based homogenizers; 2) the chloroform-DMF mixture extracts both polar CE-DNA adducts, and the less polar MPEM; 3) the acetic acid, in combination with added ascorbic acid impedes air oxidation of catechol metabolites. Thus, 4-OHE₁-1-N7Gua (CE-DNA adduct), 4-OHE₁ (CE), and 4-methoxyE₁ (MPEM) were placed on the rat tissue in 20µL of DMF containing 100 nmol of the respective compound (see Figure 1 for metabolite structures). The tissue was homogenized for 2 minutes using 20 mL of the solvent mixture. The suspension was then centrifuged, the solvent decanted, and the decanted solvent was removed by reduced pressure evaporation. The residue was then re-dissolved into 100 μL of clean DMF and a 50μL aliquot was injected on a HPLC employing a C-18 reverse phase column. The compounds were eluted using a gradient of 0.5 percent acetic acid and methanol and detected by UV absorbance (280 nm). Using standards for calibration curves, recoveries for all compounds were assayed at 80 to 90%.

In order to test this methodology on smaller samples sizes, i.e. the low picomolar range to high femtomolar range, completion of Task 2, "Develop an HPLC analytical procedure, via pre-column fluorescence derivatization, for the femtomolar detection of CE-adducts, CE and MPEM in human breast tissue", needs to be finalized. The progress on Task 2 is discussed below.

Development of a fluorescent probe specific for the catechol moiety has been approached by developing structures that can react with the vicinal hydroxy groups selectively (see Figure 2). Since the vicinal hydroxy groups can acts as nucleophiles, structures containing activated geminal dihalides have been synthesized and shown to react with catechols forming a spiro, ketal derivative. Several dihalide candidates have been developed (Year 1 and Year 2 report) with α , α -dibromomalonates showing the most promise (Figure 3). Work this past year on Task 2 has involved the synthesis of α , α -dibromomalonate esters containing anthracene and pyrene moieties, reaction of these new esters with catechol, and attachment of the anthracene fluorophore after the formation of the ketal derivative. In

addition, the synthesis of α , α -dibromomalonamides containing the anthracene fluorophore has recently been completed.

The synthesis of bis-(9-methyleneanthryl) α,α -dibromomalonate was conducted using several methods; however, the reaction of this probe with catechol proved unsuccessful. Unlike the diethyl analog (Figure 3), the dianthryl probe produced 9-anthrylmethanol as the sole product in nearly quantitative yield (Figure 4). Several variations of solvent, base, and reaction temperature were tried with no success. Bis-(1-butylpryene) α,α -dibromomalonate was also synthesized, but reaction with catechol again produce only alcohol side products. One possible difference for the reaction of the ethyl ester compared with esters containing anthracene or pyrene groups is the propensity for both anthracene and pyrene towards bromination. Dibromomalonates have been employed as brominating reagents [14].

To try to circumvent possible bromination issues, a strategy of first attaching the catechol ring to the ethyl ester, followed by hydrolysis, and then re-esterfication via a nucleophilic substitution was conducted (Figure 5). This sequence avoids exposure of the labile anthracene group to the α , α -dibromomalonate reagent. This procedure did prove successful in generating a fluorescent adduct but suffers from undesirable experimental procedures. First, this derivation scheme involves three chemical steps as apposed to one step when using α , α -dibromomalonates directly. Second, the final ketal product elutes close to the 9-bromomethylanthracene reagent. This reduces sensitivity since this reagent would be used in large excess when assaying biological samples. Third, the hydrolysis conditions using cesium hydroxide could result in reaction with other functional groups present on both CE-DNA adducts and CE. The application of this process to actual adducts is still ongoing.

The production of amide analogs of α,α -dibromomalonates is under investigation in order to produce a "one reaction" derivation procedure. The dibromomalonamides would be less reactive brominating reagents and may avoid the undesirable side products generated by the ester fluorophores. To test the reactivity of the amide analogs, bis-(N-phenyl) α,α -dibromomalonamide was synthesize and reacted with catechol (Figure 6). This reaction produced the ketal product in yields similar to diethyl α,α -dibromomalonates (Figure 3). Recently, the synthesis bis-(N-9-methlyanthranyl) α,α -dibromomalonamide has been completed (Figure 7). The reaction of this new probe with catechol is currently under investigation.

KEY RESEARCH ACCOMPLISHMENTS:

- 1) Extraction conditions for isolation of CE-DNA adducts, CE, and MPEM from rat breast tissue have been established.
- 2) Derivation procedure for fluorescence labeling of catechols has been developed using a threestep sequence of ketal formation, hydrolysis, and ester formation.
- 3) The synthesis of a dianthryl α,α -dibromomalonamide probe has been conducted.

REPORTABLE OUTCOMES:

- 1) Poster entitled, "Synthesis Of Fluorescent Probes Specific For The Catechol Moiety" was presented at the annual national spring meeting of the American Chemical Society, San Diego, CA, April 1, 2001.
- 2) Nicole Burns, an undergraduate research assitant, prented a talk at the Nebraska Academy of Sciences annual meeting entitled, "Synthesis of Fluorescent Probes Specific For The Catechol Moiety", Lincoln, NE, April 27, 2001.

3) Two Undergraduates, Stacy Hill and Nicole Burns, were employed full time during the summer of 1999, part-time during the academic year 2000/2001, and full time during the summer of 2001. Nicole Burns received her Bachelors Degree in May 2001 and will continue her studies in breast cancer research at the University of Nebraska Medical Center as a graduate student.

CONCLUSIONS:

The development of an extraction procedure capable of isolating CE-DNA adducts, CE, and MPEM from rat breast tissue has been advanced. This process is the main component of Task 1 and the only remaining issue to be addressed is performance on a smaller scale. The extraction procedure is fast and amendable to the analysis of several samples using standard laboratory equipment. This procedure should translate to the isolation of estrogen metabolites from human tissue.

The development of a fluorescent probe for catechol estrogens (Task 2) is still ongoing. A three-step process involving ketal formation, hydrolysis, and re-esterfication was successful with catechol. This process will be conducted on CE to determine the limits of detection. Synthesis of new α,α -dibromomalonamide probe has been conducted, and the use of this probe in a one-step derivation procedure is currently in progress. Once the appropriate fluorescent probe has been developed, it will be applied to the extraction procedure in Task 1 to test limits of detection in biological samples.

The development of an analytical assay capable of detecting CE-DNA adducts, CE, and MPEM at the low picomolar to high femtomolar level is necessary in order to detect these compounds at physiological levels. When completed, the analysis of human breast tissue will determine if a link between the production of CE-DNA adducts and the development of breast cancer exist. This would lead to a new biomarker for the early detection of breast cancer.

REFERENCES:

- 1) Liehr, J.G. (1990) Genotoxic effects of estrogens. *Mutat. Res.*, 238, 269-276.
- 2) Dwivedy, I., Devanesan, P.D., Cremonesi, P., Rogan, E.G., and Cavalieri, E.L. (1992) Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of the DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. *Chem. Res. Toxicol.*, *5*, 828-833.
- 3) Stack, D., Byun, J., Gross, M.L., Rogan, E.G., and Cavalieri, E.L. (1996) Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. *Chem. Res. Toxicol.*, *9*, 851-859.
- 4) Cavalieri, E., Stack D., Devanesan, P., Todorovic, R., Dwivedy, I., Higginbotham, S., Johansson, S., Patil, K., Gross, M., Gooden, J., Ramanathan, R., Cerny, R. and Rogan, E. (1997) Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. *Proc. Natl. Acad. Sci.* USA, *94*, 10937.
- 5) Spink, D.C., Eugster, H.P., Lincoln II, D.W., Schuetz, J.D., Schuetz, E.G., Johnson, J.A., Kaminsky, L.S., and Gierthy, J.F. (1992) 17 Beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: A comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. *Arch. Biochem. Biophys.*, 293, 342-348.
- 6) Liehr, J.G., Ricci, M.J., Jefcoate, C.R., Hannigan, E.V., Hokanson, J.A., and Zhu, B.T. (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implications for the mechanism of uterine tumorigenesis. *Proc. Natl. Acad. Sci, U.S.A. 92*, 9220-9224.

- 7) Liehr, J.G., and Ricci, M.J. (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. *Proc. Natl. Acad. Sci. U.S.A., 93*, 3294-3296.
- 8) Castagnetta, L.A., Granata, O.M., Arcuri, F.P., Polito, L.M., Rosati, F. and Cartoni, G.P. (1992) Gas chromatography/mass spectrometry of catechol estrogens. *Steroids*, *57*, 437-443.
- 9) Wehry, E. L. In *Practical Fluorescence*, 2nd ed,; Guilbault G. G., Ed.; Marcel Dekker, Inc.: New York, 1990; pp 117-120.
- 10) Stryer L. and Haugland L.P. (1967) "Energy Transfer: A Spectroscopic Ruler." *Proc Natl Acad Sci USA*, *58*, 719.
- 11) Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. *Annu Rev Pharmacol Toxicol 36*, 203-232.
- 12) Han X, Liehr JG (1994) 8-Hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol: role of free radicals in estrogen-induced carcinogenesis. *Cancer Res 54*, 5515-5517.
- 13) Roy D, Floyd RA, Liehr JG (1991) Elevated 8-hydroxydeoxyguanosine levels in DNA of diethylstilbestrol-treated Syrian hamsters: covalent DNA damage by free radicals generated by redox cycling of diethylstilbestrol. *Cancer Res 51*, 3882-3885.
- 14) Van der Wolf, L and Pabon, HJ (1977) A novel bromination for an unsaturated a-anion ester. Synthesis of 2-bromo-cis-8, cis-11, cis-14-eicosatrienoic acid. *Recl. Trav. Chim. 96*, 72-74.

APPENDIES:

Figure 1. Structure used to test extraction procedure.

Figure 2. Structural features of a successful fluorescent probe specific for the catechol moiety.

Figure 3. Reaction of diethyl α , α -dibromomalonate with catechol.

9-anthrylmethanol, major product

$$F_{L} = \bigoplus_{Q \in Q} F_{L} + \bigoplus_$$

Figure 4. Reaction of catechol with bis-(9-methylanthryl) α , α -dibromomalonate.

Figure 5. Three-step process for fluorescence labeling of catechols.

fluorescent derivation product

Figure 6. Reaction of catechol with bis-(N-phenyl) α , α -dibromomalonamide.

bis-(N-9-methlyanthranyl) α,α -dibromomalonamide

Figure 7. Synthesis of bis-(N-9-methlyanthranyl) α , α -dibromomalonamide